Home Newsfeeds B of A Securities Maintains Buy on Lear, Lowers Price Target to $185

B of A Securities Maintains Buy on Lear, Lowers Price Target to $185

B of A Securities analyst John Murphy maintains Lear (NYSE:LEA) with a Buy and lowers the price target from $195 to $185.

byBenzinga Newsdesk

September 9, 2022

1 minute read

B of A Securities analyst John Murphy maintains Lear (NYSE:LEA) with a Buy and lowers the price target from $195 to $185.

News

Applied DNA And The Cornell University College Of Veterinary Medicine Announce Research Collaboration To Accelerate Application Of Lineardna Platform For Veterinary Health Applications

By Benzinga Newsdesk

September 8, 10:01 AM

- Agreement Leverages Company's Ability for Intramuscular Delivery of LNP-Encapsulated LinearDNA-based Therapies for Veterinary Therapeutic and Prophylactic Applications - Applied DNA Sciences,

APDN

Utah Medical Products Q2 EPS $1.12 Up From $1.04 YoY, Sales $13.43M Up From $12.60M YoY

By Benzinga Newsdesk

July 26, 9:02 AM

Utah Medical Products (NASDAQ:UTMD) reported quarterly earnings of $1.12 per share. This is a 7.66 percent increase over earnings of $1.04 per share from the same period last year. The company reported $13.43 million in

UTMD

Barclays Downgrades Olaplex Hldgs to Equal-Weight, Lowers Price Target to $16

By Benzinga Newsdesk

August 3, 9:58 AM

Barclays analyst Lauren Lieberman downgrades Olaplex Hldgs (NASDAQ:OLPX) from Overweight to Equal-Weight and lowers the price target from $17 to $16.

OLPX

Pfizer Sees Potential Revenues Of More Than $2B From Respiratory Syncytial Virus Vaccine Candidate, Sees Peak Sales In 2027; Presentation To Begin At 1:00 p.m ET

By Benzinga Newsdesk

December 12, 1:55 PM

https://investors.pfizer.com/Investors/Events--Presentations/event-details/2022/Pfizer-Near-Term-Launches--High-Value-Pipeline-Day/default.aspx Pfizer Near-Term Launches + High-Value Pipeline Day Start date:

PFE

B of A Securities Maintains Buy on Lear, Lowers Price Target to $185

Related Posts

Applied DNA And The Cornell University College Of Veterinary Medicine Announce Research Collaboration To Accelerate Application Of Lineardna Platform For Veterinary Health Applications

Utah Medical Products Q2 EPS $1.12 Up From $1.04 YoY, Sales $13.43M Up From $12.60M YoY

Barclays Downgrades Olaplex Hldgs to Equal-Weight, Lowers Price Target to $16

Pfizer Sees Potential Revenues Of More Than $2B From Respiratory Syncytial Virus Vaccine Candidate, Sees Peak Sales In 2027; Presentation To Begin At 1:00 p.m ET